The variety inventory of be test in the near future

Source: Sina pharmaceutical 2017-09-14-1, topiramate tablet at present, only one be of Huahai pharmaceutical industry is seen on the clinical trial level platform This product is used for the treatment of epilepsy patients who are initially diagnosed as epilepsy or who have been combined with drugs and now are converted to single drug treatment This product is used for the treatment of partial epilepsy in adults and children aged 2-16 years At present, there is only one original research item listed in China - topamax 2、 Entecavir dispersible tablets - Runzhong's sales exceeded 3 billion yuan last year, and it still kept growing in the first half of this year 3、 At present, only the pramipexole tablets and sustained-release tablets originally developed by bringer Ingelheim are listed in China The patent of sustained-release tablet composition applied by the original research company in China has been authorized, and the patent expires on July 25, 2025 4、 Bunanselin's test target was included in the group, with 104 people in the domestic test; currently, only the above manufacturers have filed in chinadrugtrials.org.cn In February 2017, blonanserin, an atypical antipsychotic drug under Sumitomo pharmaceutical, obtained CFDA import drug registration license The efficacy and safety of bunanserine and risperidone in the treatment of schizophrenia were compared The study was carried out in 13 research centers in China 261 subjects were treated with bunanserine (n = 128, 8-24mg / D) or risperidone (n = 133, 2-6mg / D) for 8 weeks The results showed that at the 8th week, the total PANSS score of the two groups decreased significantly, and the therapeutic effect of the two groups was similar; the increase of prolactin in blood of the bunanselin group was significantly lower than that of the risperidone group, and the risk of heart related abnormality was also lower than that of risperidone group (12.31% vs.22.39%) Ref: the possible mechanism for bunanselin to improve cognitive function, Yukio Noda, the pharmacological mechanism of lonasen ® in the treatment of schizophrenia 5、 Clarithromycin clarithromycin is a derivative of erythromycin It was developed by Japan Dazheng pharmaceutical in the early 1990s and registered under the trade name of clarither After that, Dazheng pharmaceutical transferred its technology to Abbott for production In addition to tablets, currently produced dosage forms include granules, dispersible tablets, sustained-release tablets, injections and dry suspensions At present, only Xinhua Pharmaceutical has one be registered.